Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma (FIZZ)

The Christie NHS Foundation Trust

Status and phase

Completed

Phase 2

Conditions

Follicular Lymphoma

Treatments

Drug: 90Y Ibritumomab tiuxetan

Drug: Rituximab

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01493479

06_DOG05_33

Details and patient eligibility

About

90Y Ibritumomab tiuxetan (zevalin) has demonstrated consistently high response rates in patients who have received previous treatment for lymphoma. More than two-thirds of the patients who achieve CR go on to experience durable remissions lasting for years. Despite these highly promising clinical results with radioimmunotherapy (RIT) in relapsed follicular lymphoma there is very little data using RIT in previously untreated follicular lymphoma. The objective of this trial is to evaluate the safety and efficacy of two fractions of Zevalin in patients with previously untreated follicular lymphoma in a Phase II study.

Enrollment

76 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must have a histologically confirmed CD20 +ve follicular lymphoma grades I to IIIa.
Patients with at least one of the following symptoms requiring initiation of treatment: (as outlined by the modified BNLI/GELF criteria below)
- Nodal mass > 7cm in its greater diameter
- B symptoms
- Elevated serum LDH or beta2-microglobulin
- involvement of at least 3 nodal sites (each with a diameter > 3 cm)
- symptomatic splenic enlargement
- compressive syndrome
Patients must have an ECOG performance status less than or equal to 2 and an anticipated survival of at least 6 months.
Patients must have an absolute granulocyte count of above 1,500/mm3, and a platelet count of above 100,000/mm3 post 4 weeks of unlabelled Rituximab. A hemoglobin >= 8.0 g/dl
Patients must have adequate renal function (defined as calculated creatinine clearance > 30 ml/mn), hepatic function (defined as total bilirubin <1.5 times upper limit of normal), and hepatic transaminases (defined as AST <5 times upper limit of normal)
Patients must have given informed consent prior to study entry.

Exclusion criteria

Patients with a mean of >20% of the intratrabecular marrow space involved with lymphoma on bone marrow biopsy following induction Rituximab therapy.
Transformed follicular lymphoma and discordant lymphoma
Patients with active obstructive hydronephrosis.
Patients with initial disease bulk greater than 10cm.
Patients with evidence of active infection requiring i.v. antibiotics at the time of study entry.
Patients with congestive heart failure stage III or IV of NYHA classification, myocardial infraction or unstable angina within 6 months or other serious illness that would preclude evaluation.
Patients with left VEF < 40%
Patients with large pleural or peritoneal effusions.
Patients with known HIV infection or active HBV (HbsAg positivity) or HCV infection.
Known Hypersensitivity to murine antibodies or proteins
Patients who are pregnant or breast-feeding. Male and female patients must agree to use effective contraception for 12 months following 90Y-ibritumomab tiuxetan antibody therapy.
Patients with prior malignancy other than lymphoma, except for adequately-treated skin cancer, cervical cancer in situ, or other cancer for which the patient has been disease-free for 5 years.